β1-adrenergic receptor polymorphisms: a possible genetic predictor of bisoprolol response in acute coronary syndrome.
| Autor: | Fayed MS; Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt., Saleh MA; Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, 1181, Egypt., Sabri NA; Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt., Elkholy AA; Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Future science OA [Future Sci OA] 2023 Aug 22; Vol. 9 (10), pp. FSO895. Date of Electronic Publication: 2023 Aug 22 (Print Publication: 2023). |
| DOI: | 10.2144/fsoa-2023-0113 |
| Abstrakt: | Aim: To investigate the association between beta1-adrenergic receptor ( ADRB1 ) polymorphisms and response to bisoprolol treatment in beta-blocker naive patients with acute coronary syndrome (ACS). Patients & Methods: Seventy-seven patients received bisoprolol for four weeks. Blood pressure and heart rate were measured at baseline and during treatment. TaqMan allelic discrimination method was utilized for ADRB1 Ser49Gly and Arg389Gly genotyping. Results: Arg389Arg carriers showed greater reductions in systolic and diastolic blood pressure (-8.5% ± 7.8% vs -0.76% ± 8.7%, p = 0.000218), and (-9.5% ± 9.7% vs -0.80% ± 11.5%, p = 0.000149), respectively, compared with Gly389 carriers. No statistical difference was found for study's outcomes based on codon 49. Conclusion: Arg389Gly polymorphism is a promising bisoprolol response predictor in ACS patients. Competing Interests: Competing interests disclosure The authors declare that there are no conflicts of interest present. (© 2023 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|